Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance/Experiment 1

From BugSigDB


Reviewed Marked as Reviewed by Peace Sandy on 2024-1-23

Curated date: 2021/01/10

Curator: WikiWorks

Revision editor(s): WikiWorks, Peace Sandy

Subjects

Location of subjects
Canada
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Non-alcoholic fatty liver disease fatty liver disease, nonalcoholic,fatty liver disease, nonalcoholic, susceptibility to, 1,liver disease, alcoholic, susceptibility to, 1,NAFLD - Nonalcoholic Fatty Liver Disease,NAFLD - nonalcoholic fatty liver disease,NAFLD1,non-alcoholic fatty liver,non-alcoholic fatty liver disease,Nonalcoholic Fatty Liver Disease,nonalcoholic fatty liver disease,Non-alcoholic fatty liver disease
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Healthy control
Group 1 name Corresponds to the case (exposed) group for case-control studies
NAFLD- [non alcoholic fatty liver disease]
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Adults with biopsy-proven steatosis and non-alcoholic fatty liver disease
Group 0 sample size Number of subjects in the control (unexposed) group
28
Group 1 sample size Number of subjects in the case (exposed) group
39
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
6 Months

Lab analysis

Sequencing type
PCR
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
Not specified
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Statistical test
Metastats
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes

Alpha Diversity

Simpson Estimator of species richness and species evenness: more weight on species evenness
unchanged

Signature 1

Reviewed Marked as Reviewed by Peace Sandy on 2024-1-23

Curated date: 2021/01/10

Curator: Fatima Zohra

Revision editor(s): WikiWorks, Peace Sandy

Source: table 2

Description: Taxa identified as differentially abundant in patients with nonalocholic fatty liver disease (NAFLD) compared to HC

Abundance in Group 1: increased abundance in NAFLD- [non alcoholic fatty liver disease]

NCBI Quality ControlLinks
Lactobacillaceae
Lactobacillus
Bacilli

Revision editor(s): WikiWorks, Peace Sandy

Signature 2

Reviewed Marked as Reviewed by Peace Sandy on 2024-1-23

Curated date: 2021/01/10

Curator: Fatima Zohra

Revision editor(s): WikiWorks, Peace Sandy

Source: Table 2

Description: Taxa identified as differentially abundant in patients with nonalocholic fatty liver disease (NAFLD) compared to HC

Abundance in Group 1: decreased abundance in NAFLD- [non alcoholic fatty liver disease]

NCBI Quality ControlLinks
Alistipes
Anaerostipes
Bacillota
Bacteroidaceae
Bacteroides
Bacteroidota
Blautia
Dorea
Faecalibacterium
Lachnospiraceae
Oscillospiraceae
Porphyromonadaceae
Rikenellaceae
Coprococcus
Roseburia
Parabacteroides
Lachnospiraceae incertae sedis
Clostridia
Bacteroidales

Revision editor(s): WikiWorks, Peace Sandy